Perrigo PPA Product Withdrawal Costs Could Reach $19 Mil.
This article was originally published in The Tan Sheet
Executive Summary
FDA's request that drug companies voluntarily withdraw phenylpropanolamine-containing cough/cold remedies and appetite suppressants from the market is expected to have no significant, long-term financial impact on two major private labelers who are now reformulating products.
You may also be interested in...
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
A proposed rule on consumer topical antimicrobial products is scheduled for March 2006 release, according to HHS' semi-annual "unified agenda" published in the Federal Register Oct. 31
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
A proposed rule on consumer topical antimicrobial products is scheduled for March 2006 release, according to HHS' semi-annual "unified agenda" published in the Federal Register Oct. 31
Topical Antimicrobial Proposed Rule Slated For March in “Unified Agenda”
A proposed rule on consumer topical antimicrobial products is scheduled for March 2006 release, according to HHS' semi-annual "unified agenda" published in the Federal Register Oct. 31